Responses
Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
38 Serum proteomics signature and its association with immune-related toxicities and survival in patients with non-small cell lung cancers (NSCLC) receiving immunotherapy
Compose a Response to This Article
Other responses
No responses have been published for this article.
